O Brien Greene & Co. Inc Has $9.68 Million Stock Holdings in Danaher Co. (NYSE:DHR)

O Brien Greene & Co. Inc raised its stake in Danaher Co. (NYSE:DHR) by 2.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 38,743 shares of the conglomerate’s stock after purchasing an additional 827 shares during the quarter. Danaher accounts for 3.1% of O Brien Greene & Co. Inc’s portfolio, making the stock its 7th biggest position. O Brien Greene & Co. Inc’s holdings in Danaher were worth $9,680,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Wellington Management Group LLP lifted its position in Danaher by 12.0% in the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after purchasing an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after purchasing an additional 1,619,586 shares during the last quarter. Capital International Investors raised its holdings in shares of Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after acquiring an additional 1,334,781 shares in the last quarter. Finally, Edgewood Management LLC raised its holdings in shares of Danaher by 7.7% during the fourth quarter. Edgewood Management LLC now owns 6,381,293 shares of the conglomerate’s stock valued at $1,476,248,000 after acquiring an additional 454,950 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 1.3 %

Danaher stock opened at $272.48 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The stock has a market capitalization of $201.82 billion, a PE ratio of 46.18, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. The business’s fifty day moving average is $265.91 and its 200 day moving average is $256.78.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm posted $2.05 earnings per share. Danaher’s revenue was down 2.9% compared to the same quarter last year. On average, sell-side analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s payout ratio is 18.31%.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of a number of recent analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $300.00 target price on shares of Danaher in a report on Friday, September 6th. Barclays upped their target price on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Robert W. Baird upped their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Wells Fargo & Company initiated coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Finally, Stifel Nicolaus increased their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.